Bonacia (Hefei) Pharmaceutical Technology

The company's service portfolio is designed to support the entire clinical development lifecycle. This includes early-phase strategy and planning, clinical trial management, data management, and statistical analysis. Panacro operates in accordance with international standards such as ICH-GCP and has established detailed standard operating procedures (SOPs) to ensure quality and efficiency. A key aspect of their operations is the close cooperation with a vast network of study sites in China. In recent years, Panacro has been integrating technology into its services, developing a cloud platform for clinical trials to enhance the efficiency of new drug R&D.

Significant milestones in the company's history include introducing strategic investment in 2016 to focus on innovative drugs and biologics. In 2018, Panacro acquired Ruijie Siyuan, which led to rapid performance growth. The company has expanded its operations significantly, with offices in 20 major provinces or cities in China and a team of over 800 professionals. In 2021, Panacro appointed Mr. Zhou, a professor from Duke University's School of Medicine, as its Chief Consulting Scientist to enhance its capabilities in clinical study design and international registration. The company has also been expanding its overseas business, including the establishment of Panacro Global InnovaSolution in the United States, and in 2023 applied for a GEM listing.